HeimHLN • LON
Haleon PLC
367,10 GBX
14. jan., 17:38:06 UTC · GBX · LON · Lagalegir fyrirvarar
HlutabréfSkráð hlutabréf í GB
Við síðustu lokun
368,20 GBX
Dagbil
367,10 GBX - 372,10 GBX
Árabil
308,37 GBX - 400,65 GBX
Markaðsvirði
41,00 ma. USD
Meðalmagn
16,70 m.
V/H-hlutf.
27,90
A/V-hlutfall
1,69%
Aðalkauphöll
LON
CDP-loftslagseinkunn
B
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
(GBP)sep. 2024Breyting á/á
Tekjur
2,78 ma.-0,64%
Rekstrarkostnaður
1,04 ma.-5,01%
Nettótekjur
485,00 m.32,88%
Hagnaðarhlutfall
17,4533,82%
Hagnaður á hvern hlut
0,050,40%
EBITDA
752,75 m.3,94%
Virkt skatthlutfall
20,29%
Heildareignir
Heildarskuldir
(GBP)sep. 2024Breyting á/á
Reiðufé og skammtímafjárfestingar
531,00 m.8,37%
Heildareignir
Heildarskuldir
Eigið fé alls
16,71 ma.
Útistandandi hlutabréf
9,17 ma.
Eiginfjárgengi
2,02
Arðsemi eigna
Ávöxtun eigin fjár
6,84%
Breyting á handbæru fé
(GBP)sep. 2024Breyting á/á
Nettótekjur
485,00 m.32,88%
Handbært fé frá rekstri
Reiðufé frá fjárfestingum
Reiðufé frá fjármögnun
Breyting á handbæru fé
Frjálst peningaflæði
Um
Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England. It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers, and Centrum vitamins. The company was projected to be a global leader in over the counter medicines with a 7.3 percent market share in 2022. Haleon was established on 18 July 2022 as a corporate spin-off from GSK. Sir Dave Lewis is chairman, with Brian McNamara as CEO. Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange. Annual sales amounted to around £10 billion across 120 markets in 2020. Wikipedia
Stofnsett
18. júl. 2022
Vefsvæði
Starfsfólk
25.408
Leit
Hreinsa leit
Loka leit
Google forrit
Aðalvalmynd